PDCD1 and neoplasm: To further explore whether C.B and C.B CM can enhance the immunotherapeutic efficacy of anti-PD-1 in colorectal cancer, we established again MC38 tumor model in immune-competent C57BL/6J mice treated with C.B and anti-PD1 (Figure 6a).